BioCentury
ARTICLE | Clinical News

FDA approves Ironwood's Duzallo for gout

August 28, 2017 11:09 PM UTC

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said FDA approved Duzallo lesinurad/allopurinol to treat hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with allopurinol alone.

The company expects to launch the fixed-dose combination early next quarter, and said it will elaborate on the specific price of the drug closer to launch. Ironwood said the pricing will be similar to that of Zurampic lesinurad, one of Duzallo’s components...